North America interleukin inhibitors market is projected to grow at a modest CAGR of 9.7% during the forecast period (2024-2031). The market growth is driven by the rise in the prevalence of various diseases such as arthritis, asthma, eczema, inflammatory bowel disease (IBD), psoriasis, and others. Additionally, the well-established healthcare sector in the region creates a wide scope for market growth.
North America Interleukin Inhibitors market is segmented based on product type and applications. Based on the product type, the market is segmented into IL-1 inhibitors, IL-5 inhibitors, IL-6 inhibitors, IL-17 inhibitors, and IL-23 inhibitors. Based on the applications, the market is segmented as arthritis, asthma, eczema, Inflammatory Bowel Disease (IBD), psoriasis, and others. Further, based on geography, the North America Interleukin Inhibitors market is segmented into the US and Canada.
The US is likely to hold a significant market share during the forecast period owing to the presence of the key market players in the region. Companies such as Eli Lilly and Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck KgaA, AstraZeneca Plc, and Sun Pharmaceutical Industries Ltd. are contributing significantly to the market growth.
Browse the full report description of “North America Interleukin Inhibitors Market Size, Share & Trends Analysis Report by Product Type (IL-1 Inhibitors, IL-5 Inhibitors, IL-6 Inhibitors, IL-17 Inhibitors, and IL-23 Inhibitors), and by Application (Arthritis, Asthma, Eczema, Inflammatory Bowel Disease (IBD), Psoriasis, and Others) Forecast, 2024-2031” at https://www.omrglobal.com/industry-reports/north-american-interleukin-inhibitors-market
Recent Developments
- In September 2024, Sanofi announced the approval of Dupixent (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled Chronic Obstructive Pulmonary Disease (COPD) and an eosinophilic phenotype, by the US Food and Drug Administration (FDA). Dupixent is the first biologic medicine approved in the US to treat patients suffering from COPD.
- In September 2024, UCB S.A. announced the U.S. Food and Drug Administration (FDA) approval of BIMZELX® (bimekizumab-bkzx) for the treatment of adults with active psoriatic arthritis (PsA), adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation, and adults with active ankylosing spondylitis (AS). It is the first approved treatment designed to selectively inhibit two key cytokines driving inflammatory processes – interleukin 17A (IL-17A) and interleukin 17F (IL-17F).
- In September 2024, Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) approval of TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis (UC). It is the first and only approved fully human, dual-acting monoclonal antibody that blocks IL-23 while also binding to CD64, a receptor on cells that produce IL-23.
- In June 2024, AbbVie Inc., announced the U.S. Food and Drug Administration (FDA) approval of SKYRIZI® (risankizumab-rzaa) for adults with moderately to severely active ulcerative colitis, making it the first IL-23-specific inhibitor approved for both moderate to severe ulcerative colitis and moderate to severe Crohn's disease. The medication is approved for four indications across immune-mediated inflammatory diseases.
- In April 2024, Alvotech and Teva Pharmaceuticals, in partnership, announced the U.S. Food and Drug Administration (FDA) approval of SELARSDI (ustekinumab-aekn) injection for subcutaneous use. It can be used as a biosimilar to Stelara, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/north-american-interleukin-inhibitors-market